Lambert-Eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel

Journal of Neuroimmunology

Volumn 204, Issue 1-2, 2008, Pages 136-139

  Pellkofer, Hannah L ^a   Armbruster, Lena ^a   Krumbholz, Markus ^a   Titulaer, Maarten J ^c   Verschuuren, Jan J ^c   Schumm, Friedrich ^d   Voltz, Raymond ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Clinic for Neurology and Neurophysiology Christophsbad   (Germany)

Author keywords

Antibody; LEMS; Paraneoplastic; VGCC

Indexed keywords

ANTIBODY; RECOMBINANT PROTEIN; VOLTAGE GATED CALCIUM CHANNEL;

ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; EATON LAMBERT SYNDROME; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR DIFFERENTIATION; WESTERN BLOTTING;

AUTOANTIBODIES; CALCIUM CHANNELS, N-TYPE; FEMALE; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN STRUCTURE, TERTIARY; SMALL CELL LUNG CARCINOMA;

EID: 54349088442     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.08.002     Document Type: Article

References (27)

1. Brehm U., Piddlesden S.J., Gardinier M.V., and Linington C. Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). J. Neuroimmunol. 97 1-2 (1999) 9-15 (Jun 1)
2. Dyson H.J., Cross K.J., Houghten R.A., Wilson I.A., Wright P.E., and Lerner R.A. The immunodominant site of a synthetic immunogen has a conformational preference in water for a type-II reverse turn. Nature 318 (1985) 480-483
3. Ellinor P.T., Zhang J.F., Horne W.A., and Tsien R.W. Structural determinants of the blockade of N-type calcium channels by a peptide neurotoxin. Nature 372 6503 (1994) 272-275 (Nov 17)
4. 2+ interactions. Neuron 15 5 (1995) 1121-1132 (Nov)
5. 2+ channel diversity. Annu. Rev. Neurosci. 17 (1994) 399-418
6. Fukunaga H., Engel A.G., Lang B., Newsom-Davis J., and Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc. Natl. Acad. Sci. U. S. A. 80 24 (1983) 7636-7640 (Dec)
7. Graus F., Vincent A., Pozo-Rosich P., et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J. Neuroimmunol. 165 1-2 (2005) 166-171 (Aug)
8. Iwasa K., Takamori M., Komai K., and Mori Y. Recombinant calcium channel is recognized by Lambert-Eaton myasthenic syndrome antibodies. Neurology 54 3 (2000) 757-759 (Feb 8)
9. Komai K., Iwasa K., and Takamori M. Calcium channel peptide can cause an autoimmune-mediated model of Lambert-Eaton myasthenic syndrome in rats. J. Neurol. Sci. 166 2 (1999) 126-130 (Jul 1)
10. Lambert E.H., and Lennon V.A. Selected IgG rapidly induces Lambert-Eaton myasthenic syndrome in mice: complement independence and EMG abnormalities. Muscle Nerve 11 11 (1988) 1133-1145 (Nov)
11. Lennon V.A., Kryzer T.J., Griesmann G.E., et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N. Engl. J. Med. 332 (1995) 1467-1474
12. Leys K., Lang B., Johnston I., and Newsom-Davis J. Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann. Neurol. 29 (1991) 307-314
13. Mori Y., Friedrich T., Kim M.S., et al. Primary structure and functional expression from complementary DNA of a brain calcium channel. Nature 350 (1991) 398-402
14. O'Neill J.H., Murray N.M., and Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111 Pt 3 (1988) 577-596 (Jun)
15. Parsons K.T., and Kwok W.W. Linear B-cell epitopes in Lambert-Eaton myasthenic syndrome defined by cell-free synthetic peptide binding. J. Neuroimmunol. 126 1-2 (2002) 190-195 (May)
16. Pellkofer H., Schubart A.S., Hoftberger R., Schutze N., Pagany M., Schuller M., Lassmann H., Hohlfeld R., Voltz R., and Linington C. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain 127 8 (2004) 1822-1830
17. Rose G.D., Gierasch L.M., and Smith J.A. Turns in peptides and proteins. Adv. Protein Chem. 37 (1985) 1-109
18. Sabater L., Titulaer M., Saiz A., Verschuuren J., Güre A.O., and Graus F. SOX1 antibodies are markers of paraneoplastic Lambert Eaton myasthenic syndrome. Neurology 70 12 (2008) 924-928
19. Sher E., Gotti C., Canal N., et al. Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet 2 (1989) 640-643
20. 2+ channels: diversity of form and function. Curr. Opin. Neurobiol. 2 (1992) 247-253
21. Starr T.V.B., Prystay W., and Snutch T.P. Primary structure of a calcium channel that is highly expressed in the rat cerebellum. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 5621-5625
22. Takamori M., Hamada T., and Okumura S. Myasthenogenicity in the main immunogenic region of acetylcholine receptor as modified by conformational design: an approach to antigenic synthetic peptides. J. Neurol. Sci. 109 (1992) 182-187
23. Takamori M., Iwasa K., and Komai K. Antibodies to synthetic peptides of the alpha1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 48 5 (1997) 1261-1265 (May)
24. 2+ channel function and drug action. Trends Pharmacol. Sci. 16 2 (1995) 43-49 (Feb, Review)
25. Vincent A., Lang B., and Newsom-Davis J. Autoimmunity to the voltage-gated calcium channels underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 12 (1989) 496-502
26. Voltz R., Carpentier A.F., Rosenfeld M.R., Posner J.B., and Dalmau J. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. Muscle Nerve 22 1 (1999) 119-122 (Jan)
27. Wirtz P.W., Willcox N., van der Slik A.R., et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J. Neuroimmunol. 159 1-2 (2005) 230-237 (Feb)